Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Every little helps , DNA based vaccine with less than 10% of complete response and on average efficacy increment from 18% to 30% in comparison to Keytruda on its own. Will be interesting go to compare to SC results when published.
Rat, makes perfect sense , we must be getting RNS 2moro or in the very near future. Due to the magnitude of the event and the slot allocation it wouldn’t be unreasonable to expect top mark results which may be unique to Scancell game changer technology.
Moonparty, interesting point, the timing of the interview. The content was a good summary of where we are at present, no additional news, as this will require RNS. All we can do is read between the lines and have our own interpretation. As mentioned before good news can bare some delay as we are all sure that the next update have the potential to lift market value to a sensible level.
What’s the Nasdaq incentive?
It will require a massive consolidation (mathematical exercise ) which in theory not cause any change in fortune to PI. Possible M&A is not going to be impacted from this move. As far as open SC to the US market, yes it may attract additional investors, however that should also be the case if the ongoing trial outcome is positive or above.